放射性碘治疗甲状腺功能亢进与癌症发病及死亡风险的关联
该回顾性队列研究利用密歇根大学电子病历数据,纳入2006至2019年新诊断甲亢且无既往癌症的成人,比较放射性碘(RAI)与其他治疗对癌症发病和死亡的影响。中位随访8.2年,RAI与总体癌症发病(mv HR=1.02)及死亡(mv HR=0.81)无显著关联,但与女性乳腺癌风险升高相关(mv HR=2.24),绝经后女性更明显(mv HR=2.65)。
要点
- RAI治疗与总体癌症发病及癌症死亡无显著关联。
- RAI治疗与女性乳腺癌发病风险升高相关,绝经后女性风险更高。
- 随访≥2年者胰腺癌死亡风险升高,但结果仅为提示性。
核心结论
- RAI治疗与总体癌症发病和癌症死亡无显著关联。
- RAI治疗与女性乳腺癌发病风险升高显著相关,绝经后女性风险更高。
- 随访≥2年者胰腺癌死亡风险升高,但仅为提示性发现。
研究设计与样本
- 回顾性队列研究,利用密歇根大学去标识电子病历数据集。
- 纳入2006至2019年新诊断甲亢、无既往癌症、接受RAI、抗甲状腺药物或甲状腺切除术的成人(≥18岁)。
临床怎么用
- 对接受RAI治疗的甲亢患者,尤其是女性及绝经后女性,应关注乳腺癌长期监测。
- 胰腺癌死亡风险升高仅为提示性,需进一步研究验证。
- 临床决策时应权衡RAI治疗的长期安全性,个体化选择治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radioactive iodine (RAI) has been one of the main treatments for hyperthyroidism since the 1940s, but its long-term safety, particularly regarding cancer risk, remains controversial. This study evaluated associations between RAI treatment and cancer incidence and mortality, including overall and site-specific cancers. METHODS: We conducted a retrospective cohort study utilizing a University of Michigan de-identified electronic health record dataset. Adults (aged ≥18 years) newly diagnosed with hyperthyroidism between 2006 and 2019, without prior cancer, and treated with RAI, antithyroid medications, or thyroidectomy were included. Participants were followed until cancer diagnosis, death, or December 2022. Time-dependent Cox models estimated hazard ratios (HRs) and 95% CIs comparing RAI with other therapies using age-adjusted (age-adj) and multivariable (mv) models adjusting for demographics, lifestyle and clinical covariates. Sensitivity analysis stratified by cohort entry period, follow-up duration and restriction to ≥2 years of follow-up. RESULTS: The cohort included 6435 participants contributing 52 909 person-years (mean follow up 8.2 years; range 0.5-17 years), with 487 incident cancers and 157 cancer deaths. RAI treatment was not associated with overall cancer incidence (mv HR = 1.02 [0.76-1.47], P = .734) or cancer mortality (mv HR = 0.81 [0.45-1.44], P = .471). However, RAI was significantly associated with increased breast cancer risk among women (mv HR = 2.24 [1.21-4.17], P = .011), and among postmenopausal women (mv HR = 2.65 [1.24-5.66], P = .011). An elevated pancreatic cancer mortality was observed in those with ≥2 years of follow-up (age-adj HR = 4.05 [1.01-16.20], P = .042). CONCLUSION: RAI treatment was associated with increased breast cancer incidence but not overall cancer incidence or mortality. Findings for pancreatic cancer mortality were suggestive. These results support the importance of long-term safety monitoring among RAI-treated patients.
引用
- Momo HD, Haymart MR, Shi X, et al. Associations between radioactive iodine treatment for hyperthyroidism and cancer incidence and mortality. J Clin Endocrinol Metab. 2026. PMID: 41700975. doi:10.1210/clinem/dgag058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。